Recent news on Oxytrol

Paladin Reports 2007 First Quarter Financial Results & Increases ...  -  May 10, 2007
PharmaLive.com (press release),These increases are due primarily to strong performance from the Company's key promoted products, including Twinject®, Oxytrol®, Plan B®, Trelstar®,

FDA Recommends Precautions for Children and Elderly Taking Ditropan  -  Apr 13, 2007
Associated Content,Oxytrol, a oxybutynin transdermal system, or skin patch, is another choice. However, it cannot be used in patients with sensitive skin.

Paladin Reports Record 2006 Fourth Quarter and Year End Results  -  Feb 15, 2007
PharmaLive.com (press release),Revenues from the Company's key promoted brands including: Twinject®, Oxytrol®, Estring®, Plan B®, Trelstar®, and Pennsaid® increased by 58% in the fourth

Paladin Reports Record 2006 Fourth Quarter and Year End Results  -  Feb 15, 2007
Genetic Engineering News (press release),Revenues from the Company's key promoted brands including: Twinject(R), Oxytrol(R), Estring(R), Plan B(R), Trelstar(R), and Pennsaid(R) increased by 58% in

Paladin Reports Record 2006 Fourth Quarter and Year End Results  -  Feb 15, 2007
CCNMatthews (press release),Revenues from the Company's key promoted brands including: Twinject ® , Oxytrol ® , Estring ® , Plan B ® , Trelstar ® , and Pennsaid ® increased by 58% in

Altea Therapeutics Appoints Dr. William R. Good to its Board of ...  -  Feb 7, 2007
Business Wire (press release),...including transdermal hormone replacement products and a transdermal product for the treatment of urge incontinence, Oxytrol® (oxybutynin TTS).

Paladin and Auxilium Sign Exclusive Distribution Agreement for ...  -  Dec 12, 2006
Genetic Engineering News (press release),...strengthen our growing urology franchise which includes Oxytrol(R) and Trelstar(R)", said Jonathan Ross Goodman, President and CEO of Paladin Labs

Paladin Reports Record Revenues for Third Quarter & Increases ...  Nov 2, 2006
Revenues from the Company's key promoted brands including, Estring(R), Plan B(R), Pennsaid(R), Oxytrol(R), and Twinject(R) increased by 112% in the third ... -Genetic Engineering News (press release), Fitch Downgrades Watson's Ratings to 'BBB-'  Nov 6, 2006
...the R&D program includes promising branded pharmaceuticals, such as silodosin (with Kissei Pharmaceutical Co., Ltd.), the next generation of Oxytrol, a new ... -Business Wire (press release), Paladin Reports Record Revenues for Third Quarter & Increases ...  Nov 2, 2006
Revenues from the Company's key promoted brands including, Estring®, Plan B®, Pennsaid®, Oxytrol®, and Twinject® increased by 112% in the third quarter of ... -Market Wire (press release) Tricare, Medicare issues at forefront of defense bill  Nov 2, 2006
Seasonale, Ovacon-35, Ovacon-50, Estrostep FEG, Lyrica,Cmbatla, Lexapro, Paxil CR, Prozac Weekly, Sarafem, Wellbutin XL, Detrol, Oxytrol, Sanctura, Lexxel and ... -The Dolphin, Overactive Bladder Drugs Only Modestly Effective  Sep 10, 2006
The report finds that none of the five drugs - oxybutynin (Ditropan, Ditropan XL and Oxytrol, a skin patch); tolterodine (Detrol, Detrol LA); trospium (Sanctura ... -HealthNewsDigest.com

Part D coverage gap looms large  Sep 11, 2006
The report found none of the five drugs oxybutynin (Ditroplan, Ditroplan XL and Oxytrol, a skin patch), tolterodine (Detrol, Detrol LA), trospium (Sanctura ... -Syracuse Post Standard

Health Highlights: Sept. 6, 2006  Sep 6, 2006
People taking any of the five drugs -- oxybutynin (Ditropan, Ditropan XL and Oxytrol, a skin patch); tolterodine (Detrol, Detrol LA); trospium (Sanctura ... -Forbes

Update on hot topics in DC  Aug 31, 2006
The latest are Lexxel and Tarks, combination drugs to treat hypertension, Lyrica to treat neuropathic pain, and Detrol, Oxytrol and Sanctura to treat ... -The Dolphin

Paladin and Auxilium Sign Exclusive Distribution Agreement for ...  -  12 Dec 2006
CCNMatthews (press release),...strengthen our growing urology franchise which includes Oxytrol ® and Trelstar ® ", said Jonathan Ross Goodman, President and CEO of Paladin Labs

Paladin Reports Record Second Quarter Results and Provides Upward ...  Aug 3, 2006
Revenues from Estring ® , Oxytrol ® , Plan B ® , and Twinject ® increased by 239% in the first six months of 2006, compared to the same period a year ago. ... -CCNMatthews

Paladin Reports Record Second Quarter Results and Provides Upward ...  Aug 3, 2006
Revenues from Estring®, Oxytrol®, Plan B®, and Twinject® increased by 239% in the first six months of 2006, compared to the same period a year ago. ... -Market Wire

Generics Pump Up Watson Revenues  Aug 9, 2006
Potential upcoming sales catalysts include the cholesterol drug Pravachol and a second generation phase of Oxytrol, a bladder treatment drug. -Forbes

Manhattan Research Reveals Top Pharmaceutical Websites Visited by ...  Aug 2, 2006
Ebritux, Abilify, Novolog, Levaquin, Flomax, Herceptin, Nasonex, Clarinex, Copaxone, Seasonale, Patanol, Viread, Keppra, Lupron, Oxytrol, Symlin, Byetta, Avonex ... -Yahoo! News



Paladin Reports 2006 First Quarter Financial Results  May 11, 2006
These increases are due primarily to strong performance from the Company's key promoted products, including; Estring ® , Oxytrol ® , Plan B ® and Twinject ... - CCNMatthews

Tricare co-pay to increase for six brand-name drugs  Apr 26, 2006
The new prices for these medications will take effect July 26. • Detrol, Oxytrol and Sanctura, used to treat overactive bladder conditions. ... - ArmyTimes.com





Paladin Reports Record 2005 Fourth Quarter and Year End Results ...  Feb 22, 2006
Combined sales of the Company's key promoted brands including, Dostinex ® , Estring ® , Oxytrol ® , Plan B ® and Twinject ® increased 34% in the fourth ... - CCNMatthews,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional